CRDF
Price
$3.15
Change
-$0.01 (-0.32%)
Updated
Jun 27 closing price
Capitalization
208.56M
32 days until earnings call
ISCO
Price
$0.16
Change
-$0.00 (-0.00%)
Updated
Jun 26 closing price
Capitalization
1.26M
Interact to see
Advertisement

CRDF vs ISCO

Header iconCRDF vs ISCO Comparison
Open Charts CRDF vs ISCOBanner chart's image
Cardiff Oncology
Price$3.15
Change-$0.01 (-0.32%)
Volume$2.16M
Capitalization208.56M
International Stem Cell
Price$0.16
Change-$0.00 (-0.00%)
Volume$11.99K
Capitalization1.26M
CRDF vs ISCO Comparison Chart in %
Loading...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDF vs. ISCO commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDF is a Hold and ISCO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CRDF: $3.15 vs. ISCO: $0.16)
Brand notoriety: CRDF and ISCO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRDF: 205% vs. ISCO: 205%
Market capitalization -- CRDF: $208.56M vs. ISCO: $1.26M
CRDF [@Biotechnology] is valued at $208.56M. ISCO’s [@Biotechnology] market capitalization is $1.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDF’s FA Score shows that 0 FA rating(s) are green whileISCO’s FA Score has 1 green FA rating(s).

  • CRDF’s FA Score: 0 green, 5 red.
  • ISCO’s FA Score: 1 green, 4 red.
According to our system of comparison, ISCO is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDF’s TA Score shows that 6 TA indicator(s) are bullish.

  • CRDF’s TA Score: 6 bullish, 4 bearish.

Price Growth

CRDF (@Biotechnology) experienced а +1.61% price change this week, while ISCO (@Biotechnology) price change was +4.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

CRDF is expected to report earnings on Jul 31, 2025.

ISCO is expected to report earnings on May 16, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRDF($209M) has a higher market cap than ISCO($1.26M). ISCO YTD gains are higher at: 92.989 vs. CRDF (-27.419). ISCO has higher annual earnings (EBITDA): 111K vs. CRDF (-51.7M). CRDF has more cash in the bank: 79.9M vs. ISCO (1.45M). CRDF has less debt than ISCO: CRDF (1.36M) vs ISCO (4.1M). ISCO has higher revenues than CRDF: ISCO (9.09M) vs CRDF (587K).
CRDFISCOCRDF / ISCO
Capitalization209M1.26M16,640%
EBITDA-51.7M111K-46,580%
Gain YTD-27.41992.989-29%
P/E RatioN/AN/A-
Revenue587K9.09M6%
Total Cash79.9M1.45M5,503%
Total Debt1.36M4.1M33%
FUNDAMENTALS RATINGS
CRDF vs ISCO: Fundamental Ratings
CRDF
ISCO
OUTLOOK RATING
1..100
2050
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6040
P/E GROWTH RATING
1..100
10090
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ISCO's Valuation (5) in the null industry is somewhat better than the same rating for CRDF (66). This means that ISCO’s stock grew somewhat faster than CRDF’s over the last 12 months.

ISCO's Profit vs Risk Rating (100) in the null industry is in the same range as CRDF (100). This means that ISCO’s stock grew similarly to CRDF’s over the last 12 months.

CRDF's SMR Rating (97) in the null industry is in the same range as ISCO (100). This means that CRDF’s stock grew similarly to ISCO’s over the last 12 months.

ISCO's Price Growth Rating (40) in the null industry is in the same range as CRDF (60). This means that ISCO’s stock grew similarly to CRDF’s over the last 12 months.

ISCO's P/E Growth Rating (90) in the null industry is in the same range as CRDF (100). This means that ISCO’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDF
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
82%
MACD
ODDS (%)
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
87%
Declines
ODDS (%)
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JLCYX72.110.42
+0.59%
JHancock Fundamental Large Cap Core R2
PMVQX25.210.10
+0.40%
PGIM Quant Solutions Mid-Cap Val R6
HHDVX35.380.11
+0.31%
Hamlin High Dividend Equity Inv
FIVVX35.390.10
+0.28%
Macquarie Opportunity R6
JOGIX11.820.02
+0.17%
JOHCM Global Select Institutional

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with ABSI. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then ABSI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-0.32%
ABSI - CRDF
42%
Loosely correlated
-3.32%
MRVI - CRDF
41%
Loosely correlated
+3.78%
NAMS - CRDF
41%
Loosely correlated
+0.65%
NRIX - CRDF
40%
Loosely correlated
+0.17%
ORMP - CRDF
39%
Loosely correlated
-0.92%
More

ISCO and

Correlation & Price change

A.I.dvisor tells us that ISCO and HNSBF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ISCO and HNSBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ISCO
1D Price
Change %
ISCO100%
N/A
HNSBF - ISCO
22%
Poorly correlated
N/A
CRDF - ISCO
20%
Poorly correlated
-0.32%
IGXT - ISCO
9%
Poorly correlated
N/A
LIXT - ISCO
7%
Poorly correlated
-7.19%
INTI - ISCO
7%
Poorly correlated
-2.09%
More